National Institute for Health and Clinical Excellence (NICE)
Antibiotics should not be issued as first line of treatment for a cough, says NICE and PHE
People should take honey or cough medicines instead but speak to their GP if it persists for longer than three weeks.
Honey and over-the-counter remedies should be a patient’s first point of call to treat a cough, not antibiotics, says NICE and PHE in new draft guidance.
In most cases, acute coughs are caused by a cold or flu virus, or bronchitis, and last around three weeks.
Clinicians are advised in most cases not to offer antibiotics as they make little difference to a person’s symptoms.
Dr Tessa Lewis, GP and chair of the NICE antimicrobial prescribing guideline group said: "If someone has a runny nose, sore throat and cough we would expect the cough to settle over 2 -3 weeks and antibiotics are not needed.
“People can check their symptoms on NHS choices or NHS Direct Wales or ask their pharmacist for advice.
“If the cough is getting worse rather than better or the person feels very unwell or breathless then they would need to contact their GP."
There are self-care products that people can take to manage their symptoms themselves.
Honey and cough medicines containing pelargonium, guaifenesin or dextromethorphan have some evidence of benefit for the relief of cough symptoms.
The NICE draft guidance states it is important the reasons for not giving an antibiotic are clearly explained by the healthcare professional and advice is given to the patient on appropriate self-care.
Dr Susan Hopkins, healthcare-associated infection and antimicrobial resistance deputy director at Public Health England, said: “Antibiotic resistance is a huge problem and we need to take action now to reduce antibiotic use. Taking antibiotics when you don’t need them puts you and your family at risk of developing infections which in turn cannot be easily treated.
“These new guidelines will support GPs to reduce antibiotic prescriptions and we encourage patients to take their GPs advice about self-care.”
An antibiotic may be necessary for acute cough when a person has been identified as being systematically unwell or if they are at risk of further complications for example, people with a pre-existing condition such as lung disease, immunosuppression or cystic fibrosis.
Clear information about the most appropriate choice of antibiotic and duration of the course are outlined in the new guideline.
Professor Mark Baker, director of the centre for guidelines at NICE said: “We are keen to highlight that in most cases, antibiotics will not be necessary to treat a cough. We want people to be offered advice on alternatives that may help ease their symptoms.
“When prescribing antibiotics, it is essential to take into account the benefit to the patient and wider implications of antimicrobial resistance, only offering them to people who really need them.
“This guideline gives health professionals and patients the information they need to make good choices about the use of antibiotics. We encourage their use only when a person is at risk of further complications.”
This draft guideline is part of a suite of antimicrobial prescribing guidance developed with Public Health England to help manage common infections and prevent antimicrobial resistance. Information about managing sinusitis, sore throat and otitis media can be found on our website.
The consultation for this acute cough guideline closes on the 20th September 2018.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
NICE calls for healthcare professionals to use shared decision making best practice to highlight the risks of medicines associated with dependence25/10/2021 14:15:00
NICE is advising doctors, nurses and pharmacists to discuss with patients the risks of prescribing them medicines including opioids, sleeping pills and antidepressants.
NICE announces next steps for publication of its guideline on ME/CFS20/10/2021 14:20:00
NICE has today (20 October 2021) announced the next steps for publication of its updated guideline on the diagnosis and management of myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome (ME/CFS)
New draft guideline to help reduce health inequalities in people experiencing homelessness07/10/2021 09:15:00
NICE and the Centre for Homelessness Impact (CHI) have jointly published a new draft guideline to increase the access people experiencing homelessness have to health and social care services and improve their health outcomes.
NICE updates managing COVID guideline with new monoclonal antibody recommendations06/10/2021 11:15:00
NICE has updated its managing COVID-19 guideline to include new recommendations on using monoclonal antibodies to treat COVID-19 patients in hospital.
NICE recommends first treatment in two decades for sickle cell disease05/10/2021 11:15:00
Hundreds of people will be eligible for a new treatment for sickle cell disease following draft guidance published today (5 October).
People with advanced or metastatic urothelial cancer to get life-extending treatment01/10/2021 11:15:00
Around 130 people per year with untreated locally advanced or metastatic urothelial cancer will be eligible for a new life-extending treatment after NICE published final draft guidance yesterday (30 September 2021) recommending atezolizumab.
Update on the NICE ME/CFS guideline roundtable discussion22/09/2021 09:10:00
The roundtable meeting to discuss the updated guideline on the diagnosis and management of ME/CFS will be held on October 18th in London. It is being convened after publication of the guideline was paused when issues were raised by some professional groups during the pre-publication period
NICE and PHE recommend all employers give mental health training for managers17/09/2021 11:10:00
All managers should be given the skills to support employees with mental health issues, NICE and PHE have said in new guidance.
NICE recommends treatment for people with juvenile idiopathic arthritis10/09/2021 11:15:00
NICE yesterday (9 September 2021) published final draft guidance which recommends tofacitinib (also known as Xeljanz and made by Pfizer) as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people 2 years and older.